AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind. The ‘heart-in-a-jar’, Novoheart’s proprietary 3D human ventricular cardiac organoid chamber (hvCOC) technology, will be made from human stem cells and will replicate the key characteristics of heart failure. This will include preserved ejection fraction
Hertfordshire Local Enterprise Partnership announced plans to invest an extra £1.2 million into Stevenage Bioscience Catalyst (SBC), in order to “help grow a world-class cell and gene therapy cluster.” The money will help reinforce the campus as a world class cell and gene therapy cluster, providing much-needed temporary accommodation for growing companies of that nature.
Oxford Drug Design (ODD) has won a UK-China antimicrobial resistance grant, in addition to also boosting its funding with investment from the Angel CoFund. Oxford Drug Design Limited has raised a combined £2.2m in funding from the Angel CoFund (ACF), o2h Ventures and other new investors. Whilst also gaining grant funding from the UK Department
